Review: AI across the aging continuum, from hallmarks to clinical care
This review describes how artificial intelligence is used in aging research, from hallmark-based biomarker discovery to clinical deployment, and argues that validation rigor and ethical infrastructure are core scientific determinants. [1]
Automatic summary · not editorially reviewed
The key findings
The review says AI uses multi-omics, spatial biology, imaging and clinical data to reveal nonlinear structures linking hallmark interactions to tissue vulnerability and organismal decline. [1]
The review says AI supports synthetic data generation, cross-disease repurposing and personalized geriatric care through digital phenotyping and predictive analytics. [1]
The review calls for hierarchical experimental validation and explainable AI to distinguish causal mechanisms from epiphenomena. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Aging biology and geroscience, including vulnerable aging populations
- Summary based on
- Study abstract
AI links aging hallmarks to tissue vulnerability
The review states that aging arises from nonlinear interactions among primary, antagonistic and integrative hallmarks that progressively erode tissue resilience. It says AI uses multi-omics, spatial biology, imaging and clinical data to reveal nonlinear structures linking hallmark interactions to tissue vulnerability and organismal decline. These mechanistic insights are said to inform target prioritization, perturbation-based pathway modeling and rational design of multi-target geroprotectors, including compounds already advancing through clinical trials.
Supporting source [1]
Repurposing, synthetic data and geriatric care
Beyond discovery, the review says AI supports synthetic data generation, cross-disease repurposing and personalized geriatric care through digital phenotyping and predictive analytics. It presents these as described capabilities of AI in geroscience, not as demonstrated clinical benefits.
Supporting source [1]
Data pitfalls, bias and validation demands
The review warns that advances hinge on confronting challenges in data quality, confounding variables, batch effects and technical artifacts that risk encoding spurious correlations. It calls for hierarchical experimental validation and explainable AI to distinguish causal mechanisms from epiphenomena. It also names algorithmic bias, digital ageism, privacy vulnerabilities and infrastructural inequalities as threats that could exacerbate disparities among vulnerable aging populations.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract describes proposed uses and challenges of AI in geroscience without reporting study designs, sample sizes, follow-up or outcome data. Statements about geroprotectors in clinical trials and about clinical deployment are not accompanied by results, and no causal or clinical benefit is established here.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Hongbo Li, Peace Osebhue Abhulimen, Qiuliyang Yu, Wenxiang Cheng, Lucy Wanjiru Njunge · doi.org